Lp-PLA2 as a marker of cardiovascular diseases

Current Atherosclerosis Reports

Volumn 12, Issue 2, 2010, Pages 140-144

  Bhatti, Sabha ^a   Hakeem, Abdul ^a   Cilingiroglu, Mehmet ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Cardiovascular diseases; Lp PLA2; Phospholipase A2

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BIOLOGICAL MARKER;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; GENETIC ASSOCIATION; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; BLOOD; CARDIOVASCULAR DISEASES; ENZYMOLOGY; INCIDENCE; LIPID PEROXIDATION; RISK ASSESSMENT; RISK FACTOR; VASCULAR ENDOTHELIUM;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; INCIDENCE; LIPID PEROXIDATION; RISK ASSESSMENT; RISK FACTORS;

EID: 77953539979     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-010-0095-6     Document Type: Review

References (20)

1. Kolodgie FD, Burke AP, Skorija KS et al.: Lipoprotein- associatedphospholipase A2 protein expression in the natural progression ofhuman coronary atherosclerosis. Arterioscler Thromb Vasc Biol2006, 26:2523-2529.
2. Carpenter KL, Dennis IF, Challis IR, et al.: Inhibition oflipoprotein-associated phospholipase A2 diminishes the death inducing effects of oxidised LDL on human monocytemacrophages.FEBS Lett 2001, 505:357-363
3. Quarck R, De Geest B, Stengel D, et al.: Adenovirus-mediatedgene transfer of human platelet-activating factor-acetylhydrolaseprevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation2001, 103:2495-2500.
4. 2 in initiation and progression of atherosclerosisand CAD.
5. Chen CH: Platelet-activating factor acetylhydrolase: is it good orbad for you? Curr Opin Lipidol 2004, 15:337-341.
6. Stafforini DM, Satoh K, Atkinson DL, et al.: Platelet-activatingfactor acetylhydrolase deficiency. A missense mutation near theactive site of an anti-inflammatory phospholipase. J Clin Invest1996, 97:2784-2791
7. Ishihara M, Iwasaki T, Nagano M, et al.: Functional impairment oftwo novel mutations detected in lipoprotein-associated phospholipaseA2 (Lp-PLA2) deficiency patients. J Hum Genet 2004, 49:302-307.
8. Abuzeid AM, Hawe E, Humphries SE, et al., for the HIFMECHStudy Group: Association between the Ala379Val variant of thelipoprotein associated phospholipase A2 and risk of myocardialinfarction in the north and south of Europe. Atherosclerosis 2003,168:283-288.
9. Brilakis ES, Joseph P, et al.: Association of lipoprotein- associatedphospholipase A2 levels with coronary artery disease risk factors,angiographic coronary artery disease, and major adverse events atfollow-up. Eur Heart J 2005, 26:137-144.
10. Caslake MJ, Packard CJ, Suckling KE, et al.: Lipoproteinassociatedphospholipase A(2), platelet-activating factor acetylhydrolase:a potential new risk factor for coronary artery disease.Atherosclerosis 2000, 150:413-419.
11. Oei H-H, van der Meer IM, Hofman A, et al.: Lipoproteinassociatedphospholipase a2 activity is associated with risk ofcoronary heart disease and ischemic stroke: the Rotterdam Study.Circulation 2005, 111:570-575.
12. Kiechl S, Willeit J, Mayr M, et al.: Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity,and 10-year outcomes: prospective results from the Bruneckstudy. Arterioscler Thromb Vasc Biol 2007, 27(8):1788-1795.
13. Suzuki T, Solomon C, Jenny NS, et al.: Lipoprotein- associatedphospholipase A(2) and risk of congestive heart failure in olderadults: the Cardiovascular Health Study. Circ Heart Fail 2009,2:429-436.
14. 2 and prognosis after myocardial infarction in thecommunity. Arterioscler Thromb Vasc Biol 2006, 26:2517-2522.
15. 2 and its rolein CVD.
16. Iribarren C, Gross MD , Darbinian JA, et al.: Association oflipoprotein-associated phospholipase A2 mass and activity withcalcified coronary plaque in young adults: the CARDIA study.Arterioscler Thromb Vasc Biol 2005, 25:216-221.
17. MacPhee CH: Lipoprotein-associated phospholipase A2: a potentialnew risk factor for coronary artery disease and a therapeutictarget. Curr Opin Pharmacol 2001, 1:121-125.
18. Boyd HF, Fell SC, Hickey DM, et al.: Potent, orally activeinhibitors of lipoprotein-associated phospholipase A(2): 1-(biphenylmethylamidoalkyl)- pyrimidones. Bioorg Med Chem Lett 2002,12:51-55.
19. Sudhir K: Clinical review: lipoprotein-associated phospholipaseA2, a novel inflammatory biomarker and independent riskpredictor for cardiovascular disease. J Clin Endocrinol Metab 2005, 90:3100-3105.
20. Serruys PW, Garcia-Garcia HM, Buszman P, et al.: Effects of thedirect lipoprotein-associated phospholipase A(2) inhibitor darapladibon human coronary atherosclerotic plaque. Circulation2008, 118:1172-1182. This article outlines the direct inhibition ofLp-PLA2 using darapladib and its effect of plaque progression.